Pharm-Olam International Ltd. (POI), a multi-national CRO to pharmaceutical, biotechnology and medical device industries, announced the award of new contracts with an aggregate value over $25 million. The new contracts involve patient recruitment, site selection, data management, monitoring, and regulatory affairs in a variety of indications including lung cancer, rheumatoid arthritis, and thromboembolism.
